See how a clinical chart becomes an order-ready genetic-testing recommendation — step by step.
Two CPIC drug–gene interactions identified from the active medication list; ordering supported by a documented indication.
Personal-history coding present; family history supportive. Confirm testing criteria before ordering.
ScreenMyGene converts unstructured clinical documentation into a defensible genetic-testing recommendation — reasoning over the whole chart, not searching a catalog.
Paste a note, upload a record, or batch several patients at once. ScreenMyGene does the reading, the reasoning, and the coding.
Paste a note, upload a PDF, or batch up to five charts. OCR lifts text from scanned records and requisitions.
A clinical language layer structures diagnoses, medications, family history, phenotype and prior testing.
Tiered rule engines map the chart to qualifying panels across every supported specialty.
A documented, non-generic ICD-10 must support each panel; safety gates and coverage rules apply.
Qualified and potentially-qualified panels arrive with a clear, defensible rationale.
Upload up to five patients, review and edit each extracted chart, add labs, then analyze together. Every result lands in your history, one click apart.
Every recommendation traces to an established source of truth — never a black box.
Drug–gene guidance from the Clinical Pharmacogenetics Implementation Consortium. Panels qualify from real medication exposures — never a single gene alone.
Diagnosis codes are validated to the character. A recommendation stands only when the chart carries a documented, matching, non-generic code.
Panel content is curated against ClinGen, GenCC and PanelApp-style validity, so every test reflects an established gene–disease relationship.
Logic aligned to Medicare local and national coverage determinations and payer medical-necessity criteria, so recommendations are order-ready.
CPIC-aligned drug–gene matching from the active medication list.
Qualifies multi-gene PGx panels when supported drug exposures are present — and never emits a lone CYP gene as a standalone test.
Panel selection grounded in personal and family history.
Aligns to professional-society testing criteria; family history is treated as a supportive factor, not a sole qualifier.
Hereditary neuropathy, epilepsy and related presentations.
Tier-1 evaluators with structural- and reversible-cause safety gates that keep recommendations clinically appropriate.
Inherited metabolic and storage disorders.
Phenotype- and diagnosis-driven logic for conditions such as Wilson disease and related inborn errors of metabolism.
Inherited cardiac and related conditions.
Curated gene–disease validity keeps cardiogenetic panels aligned to established relationships and current frameworks.
Up to five patients in a single, reviewable pass.
Read and edit each extracted chart, add labs, then analyze together — results land in your history, one click apart.
Triage inbound orders, cut avoidable denials, and standardize medical-necessity documentation before a sample is run.
A consistent, auditable basis behind every recommended panel — reproducible across the team and ready for review.
Faster chart triage means less time reconciling catalogs and coverage rules, and more time where it matters.
The right test without memorizing the genomic menu — surfaced with the reasoning behind it.
Policy-aware genomic ordering across a population, without trading away consistency or safety.
Recommendations arrive supported by a documented diagnosis, reducing denials and downstream rework.
ScreenMyGene assists qualified professionals; it never replaces independent clinical judgment.
Every recommendation traces back to the finding and the code that produced it.
Designed for de-identified and synthetic data in evaluation, and controlled clinical environments in use.